Modality
mAb
MOA
JAK1i
Target
TIGIT
Pathway
Proteasome
HNSCCCrohn's
Development Pipeline
Preclinical
Sep 2024
→ Feb 2031
PreclinicalCurrent
NCT07651256
558 pts·Crohn's
2024-09→2031-02·Terminated
558 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-02-164.9y awayInterim· Crohn's
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Preclinical
Termina…
Catalysts
Interim
2031-02-16 · 4.9y away
Crohn's
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07651256 | Preclinical | Crohn's | Terminated | 558 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| ARG-1924 | Argenx | Preclinical | DLL3 |